Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07410975 2026-02-13

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Phase 2 Recruiting

54 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07243951 2025-11-24

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

75 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Liver Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2 Not yet recruiting

48 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT05571293 2025-07-30

NEST-1

Phase 2 Suspended

36 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT06494995 2025-06-04

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Phase 2 Recruiting

52 enrolled

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck

NCT05490719 2024-05-21

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Phase 2 Recruiting

39 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02970981 2024-04-30

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Phase 2 Completed

18 enrolled 8 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT05990231 2023-09-11

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Phase 2 Unknown

35 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma

NCT01896869 2020-05-19

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Phase 2 Completed

83 enrolled 16 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

NCT01331525 2016-04-14

ICE

Phase 2 Completed

42 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

Clinical Trials

PHOENIX

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

NEST-1

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

ICE